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Abstract
Background: Clinical guidelines carry medical evidence to the point of practice. As evidence is not always
available, many guidelines do not provide recommendations for all clinical situations encountered in
practice. We propose an approach for identifying knowledge gaps in guidelines and for exploring
physicians' therapeutic decisions with data mining techniques to fill these knowledge gaps. We
demonstrate our method by an example in the domain of type 2 diabetes.
Methods: We analyzed the French national guidelines for the management of type 2 diabetes to identify
clinical conditions that are not covered or those for which the guidelines do not provide
recommendations. We extracted patient records corresponding to each clinical condition from a database
of type 2 diabetic patients treated at Avicenne University Hospital of Bobigny, France. We explored
physicians' prescriptions for each of these profiles using C5.0 decision-tree learning algorithm. We
developed decision-trees for different levels of detail of the therapeutic decision, namely the type of
treatment, the pharmaco-therapeutic class, the international non proprietary name, and the dose of each
medication. We compared the rules generated with those added to the guidelines in a newer version, to
examine their similarity.
Results: We extracted 27 rules from the analysis of a database of 463 patient records. Eleven rules were
about the choice of the type of treatment and thirteen rules about the choice of the pharmaco-therapeutic
class of each drug. For the choice of the international non proprietary name and the dose, we could extract
only a few rules because the number of patient records was too low for these factors. The extracted rules
showed similarities with those added to the newer version of the guidelines.
Conclusion: Our method showed its usefulness for completing guidelines recommendations with rules
learnt automatically from physicians' prescriptions. It could be used during the development of guidelines
as a complementary source from practice-based knowledge. It can also be used as an evaluation tool for
comparing a physician's therapeutic decisions with those recommended by a given set of clinical guidelines.
The example we described showed that physician practice was in some ways ahead of the guideline.
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Background
Clinical guidelines are useful decision support tools for
physicians. Their purpose is to bring medical evidence to
the point of practice. Physicians need to make clinical
decisions based on the available evidence, but they also
have to act when such evidence is absent. In many situa-
tions, good clinical evidence is impossible, unethical,
impractical, or too expensive to generate [1]. As a result,
guidelines cannot always provide recommendations for
all the possible clinical situations that they are supposed
to cover [2]. For example, the French national guidelines
for the management of type 2 diabetes mellitus recom-
mends starting oral bitherapy for patients whose HbA1c
remains above 6.5% after six months of treatment with
maximum dose oral monotherapy [3]. However, it leaves
the choice of the appropriate combination of oral anti-
diabetic drugs to the physicians' discretion according to
their appreciation of the risk/benefit for each patient. This
type of situation, where the guidelines "stop" at a certain
level and leave the decision to the physician, is common.
Unfortunately, it is not always easy for physicians – espe-
cially the less experienced – to assess the risk/benefit of
each decision in every patient. It would therefore be useful
to explore experienced physicians' prescriptions and to
analyze how they react in diverse cases with various clini-
cal conditions. This information could then be used to
help less experienced physicians with their clinical deci-
sion-making.
In our example of type 2 diabetes, the guidelines take a
clinical situation into account, but come short of provid-
ing full guidance for that situation. Sometimes, guidelines
do not take into account a possible patient condition. For
example, a former version of the same type 2 diabetes
guidelines state that there is no benefit in prescribing an
oral tritherapy for a patient whose HbA1c remains above
8% after six months of bitherapy at maximum dose [4].
However, the guidelines do not provide guidance about
what to do if such a patient is already under treatment
with tritherapy (whether the tritherapy should continue,
or be switched to bitherapy, or to insulin therapy). The sit-
uation is simply not considered by the guidelines.
Many approaches have been proposed to prevent struc-
tural knowledge gaps in guidelines [5]. Some involve
guidelines authors following standard structures when
developing the guidelines, so as not to leave out any pos-
sible patient conditions [6]. Others propose using tools
for modeling guidelines such that they can be interpreted
by computer, and thus have a more robust logical struc-
ture [7]. These approaches help considering possible
patient conditions, but they cannot cope with an absence
of medical evidence and there are still patient conditions
for which modern guidelines do not propose appropriate
recommendations [8].
Using the large databases of electronic patient records
now available, it is possible to use data mining and
knowledge discovery techniques to identify common
therapeutic decisions made by physicians for a given clin-
ical condition. There have been some limited attempts at
using these techniques for generating practice guidelines
from data. Mani et al. [9] presented a two-stage machine
learning model as a data mining method to develop clin-
ical practice guidelines, and showed its value in staging
dementia. They modeled the methodology used by clini-
cians by deriving intermediate concepts in the first phase,
and in the second phase they used the intermediate con-
cepts for staging dementia. However, the dementia scor-
ing scale that they learnt led to a less complex guideline
than those usually implemented in other domains. It is
also not clear whether their method can be generalized to
different domains. Morik et al. [10] used a combination of
prior knowledge from experts and learning from data to
generate protocols automatically for decision support in
intensive care. They used support vector machines (SVM)
to learn the appropriate dose adjustment for each contin-
uously administered drug, based on the response of the
patient's vital signs to that change. They then verified the
learnt dose adjustment against a medical knowledge base.
However, the resulting protocol was again much less com-
plex than most guidelines. In another attempt, Mani et al.
[11] used C4.5 and Ripper algorithms with a database of
369 patients and showed that data mining methods could
be used for generating simple guidelines and checking
compliance to guidelines. Nevertheless, the guidelines
resulting from these efforts for creating entire guidelines
from data only handle simple problems and lack detail
and readability.
Most importantly, guidelines should be evidence-based
by definition, and methods aiming at extracting guide-
lines from data should consider existing evidence-based
recommendations. Therefore, another approach can be
viewed as filling knowledge gaps of the guidelines rather
than replacing them entirely.
Our goal was to develop a method for exploring physi-
cians' therapeutic decisions by use of data mining tech-
niques only in situations for which clinical guidelines do
not provide recommendations. We explain the method
using the French national guidelines for type 2 diabetes
management, and an example database of diabetic patient
records. We do not aim at providing medical knowledge
from this example.
Methods
The guideline
We used the French national guidelines for the manage-
ment of type 2 diabetes published by the French National
Authority for Health (HAS) [4]. A newer version of thisBMC Medical Informatics and Decision Making 2009, 9:28 http://www.biomedcentral.com/1472-6947/9/28
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guideline was released in 2006 [3]; nevertheless, we ana-
lyzed the rules of the previous version, because our patient
database was compiled during 2003 and 2004, and also
because we wanted to be able to compare the rules
extracted by our method with those added to in newer ver-
sion of the guidelines. The studied guidelines propose a
step-by-step treatment strategy for achieving a treatment
goal, which is defined by the level of HbA1c. If the goal is
not achieved by the ongoing treatment, the physician
must step forward to the following types of treatment. The
types of treatment consist of diet and exercise, oral mono-
therapy, oral bitherapy, and insulin therapy alone or with
oral anti-diabetic drugs. At each step, the guidelines rec-
ommend considering an increase in the dose and then a
change in the pharmaco-therapeutic class of the ongoing
medication, before advancing to the next step. Many of
the recommendations are provided with their level of evi-
dence.
The patient database
We used a de-identified database of electronic records of
ambulatory patients admitted to the Avicenne university
hospital in Bobigny, France, for management of their type
2 diabetes, from June 2003 to September 2004. Patients
attended the hospital for routine testing of their diabetes
or because of its deregulation. They stayed a few hours in
the hospital during which time they underwent laboratory
tests and consulted a senior staff physician from the
department of diabetes care. During the visit, physicians
either confirmed the ongoing treatment or changed it.
They had access to the guidelines in paper and electronic
forms (downloadable .pdf file available at the official HAS
website) when entering information into the database. In
the database, each patient record contains 125 attributes
including administrative (age, sex, consulting physician,
physician in charge), anthropometric (weight, height,
weight 6 months before, weight at the time of diagnosis,
etc), clinical (past or current history of hypertension, cor-
onary artery disease, dyslipidemia, renal insufficiency, cer-
ebrovascular accident, ophthalmopathy, neuropathy, foot
problems, smoking, alcohol consumption, level of physi-
cal activity, diet, etc), laboratory (HbA1c, morning glyc-
emia, postprandial glycemia, creatinine clearance,
microalbuminuria, uricemia, cholesterolemia, etc) and
therapeutic (past and current treatments) data. All patient
records used in the study were collected for the real prac-
tice purposes and not for the study. The retrospectively
extracted records were de-identified before being trans-
ferred to the authors. As we had no access to the hospital
database, nor did we seek any complementary informa-
tion on patients or doctors (the patient records were com-
pletely anonymous), the approval of the study by an
ethics committee – beyond the usual declaration made by
hospital authorities for the use of patient data – was not
necessary.
Formalizing prescriptions
To facilitate the generation of rules by decision-tree learn-
ing algorithms, we formalized the prescriptions by imple-
menting a typology model for drug therapy as described
previously [12]. In this model, a drug therapy consists pri-
marily of a type of treatment, which is defined as any com-
bination of drugs (including none) prescribed for a given
disease. For example, in type 2 diabetes management,
treatment types are classified as diet and exercise, mono-
therapy, bitherapy, tritherapy, and insulin therapy alone
or with oral anti-diabetic drugs. Each type includes a com-
bination of a number (including zero) of drugs having
attributes such as pharmaco-therapeutic class, interna-
tional non-proprietary name (INN), and dose.
Analyzing the guidelines for missing or incomplete rules
Following Shiffman et al. [13], we formalized recommen-
dations of the guidelines as conditions and actions. We
expressed the actions using the typology model for drug
therapy described above. We identified all patient varia-
bles which were dealt with by the guidelines. We enumer-
ated possible values for each variable and created a table
of possible combinations of patient profiles to check
whether they were all covered by the guidelines. When
possible, we merged some of these profiles into one bigger
profile by combining their attributes, in the same as done
in the guidelines. For example, in the case of recommen-
dations for metformine prescription, the guidelines merge
"renal insufficiency (yes/no)" and "body mass index
(BMI) ≥ 28 (yes/no)" into a new attribute of "no renal
insufficiency and BMI ≥ 28 (yes/no)" such that only a sin-
gle (composite) condition has to be verified prior to met-
formine prescription. In this way, the number of absolute
combinations of renal insufficiency and BMI attributes is
reduced from 4 to 2.
Selecting patient records related to missing or incomplete 
rules
We selected patient records that corresponded to missing
or incomplete rules in the guidelines. For example, for
patients under treatment with monotherapy with HbA1c
above 8%, the guideline recommended bitherapy, with-
out mentioning a preferred combination of pharmaco-
therapeutic classes. We extracted all patient records which
met this condition from the data base to analyze the pref-
erences of physicians in this group of patients. We pro-
ceeded in the same way for all patient profiles
corresponding to missing or incomplete rules.
Generating rules
We used Quinlan's C5.0 decision-tree learning algorithm
[14] to generate a set of rules for each subgroup of patient
records associated with missing or incomplete rules in the
guidelines. We did this in four steps aimed at progres-
sively seeking more detailed rules. First, we implementedBMC Medical Informatics and Decision Making 2009, 9:28 http://www.biomedcentral.com/1472-6947/9/28
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the decision-tree learning algorithm to extract rules for the
type of treatment for patient profiles for which the guide-
lines did not provide complete recommendations about
treatment type. Then, we extracted rules for the choice of
pharmaco-therapeutic class of drugs for patient profiles
for which the rules on the choice of the pharmaco-thera-
peutic class of drugs were missing or incomplete, but
where the type of treatment was recommended either by
the guidelines or by the rules learnt during the previous
step. In the third step, we used the decision-tree learning
algorithm to extract rules for the choice of the drug,
according to its international non proprietary name
(INN), for patient profiles for which the choice of the type
of treatment and the pharmaco-therapeutic classes of
medications were recommended either by the guidelines
or the rules learnt during the previous steps. Finally, we
used the learning algorithm to extract rules for the dose of
each medication for patient profiles for which the choice
of the type of treatment, the pharmaco-therapeutic class
and the INN of each drug were recommended by the
guidelines or could be calculated using the rules learnt in
the previous steps.
Machine learning methods and options
A C5.0 model works by splitting the sample according to
the field that provides the maximum information gain.
Each subsample defined by the first split is then split
again, usually according to a different field, and the proc-
ess repeats until the subsamples cannot be split any fur-
ther. The lowest-level splits are then reexamined, and
those that do not contribute significantly to the value of
the model are removed or pruned. We used the C5.0 node
of the SPSS Clementine® software version 10.1 [15] for
machine learning computations.
The C5.0 node can produce two kinds of models: a deci-
sion tree which is a straightforward description of the
splits found by the algorithm; and a rule set which tries to
make predictions for individual records. We chose the first
option because it assigns each individual to a single termi-
nal node; whereas an individuals' profile may be associ-
ated with more than one rule. Consequently, decision
trees are more useful than induced rules for making clini-
cal decisions [16]. To train the C5.0 model, we considered
prescription as a dependent variable (In field), and all
other variables as independent ones (Out fields).
We used the Simple Mode option of the C5.0 node which
sets most of the C5.0 parameters automatically; these
parameters are: pruning severity, minimum records per
child branch, global pruning, and Winnow attributes. We
set the Favor option of the Simple Mode to generate the
most accurate tree possible. We left the Expected Noise
option as the default value (0% for the expected propor-
tion of noisy or erroneous data in the training set),
because we had thoroughly cleaned our data set prior to
use.
We also used the boosting capability of the C5.0 algo-
rithm to improve its accuracy. Boosting works by building
multiple models in a sequence. The first model is built in
the usual way. A second model is then built in such a way
that it focuses especially on the records that were misclas-
sified by the first model. Then a third model is built to
focus on the second model's errors, and so on. Finally,
cases are classified by applying the entire set of models,
using a weighted voting procedure to combine the sepa-
rate predictions into one overall prediction. This process
of boosting can significantly improve the accuracy of a
C5.0 model, but it also requires longer training. We set the
number of models to be used for the boosting to ten.
Finally, we used the cross validation option of the C5.0
node. It uses a set of models built on subsets of the train-
ing data to estimate the accuracy of a model built on the
full data set. This is useful if the data set is too small to
split into traditional training and testing sets. We set the
number of models used for cross validation to ten.
Results
Analyzing the guidelines
We analyzed the guidelines by formalizing all the recom-
mendations in conditions and actions, and represented
them in a decision-tree (Figure 1).
Identification of missing or incomplete rules in the 
guidelines
The guidelines use the following variables to describe
patient conditions: acute clinical symptoms (yes or no);
HbA1c (three ranges: less than or equal to 6.5%, between
6.6% and 8%, and greater than 8%); type of current treat-
ment (four types: diet and exercise, monotherapy, bither-
apy, and insulin therapy alone or with oral anti-diabetic
drugs); body mass index (BMI) (two ranges: less than 28,
greater than or equal to 28); the existence of renal insuffi-
ciency (yes or no); and being old (yes or no). We calcu-
lated all combinations of these variables to check if all of
them were dealt with by the guidelines. A total of 192
combinations were possible with these variables, but we
reduced them to 16 patient profiles (or clinical condi-
tions, designated 1 to 16 hereafter) by merging similar
variables, and by using "any" as a denominator when a
variable was not dealt with in a particular rule (Table 1).
We distinguished two kinds of knowledge gaps in the
guidelines: missing rules and incomplete rules. Missing
rules are associated with conditions  which are not
addressed in the guidelines: if a patient condition is not
included in the guidelines, then necessarily no corre-
sponding action is proposed. For example, if the condi-BMC Medical Informatics and Decision Making 2009, 9:28 http://www.biomedcentral.com/1472-6947/9/28
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tion of patients who come to the doctor under tritherapy
is not mentioned in the guideline, the corresponding
action to be taken for these patients will also be missing,
and the whole rule is therefore missing. Incomplete rules
are those related to existing conditions for which the rec-
ommended action  is missing, incomplete or imprecise.
Another, better elaborated action is therefore required for
an incomplete rule. For example, the condition of patients
under monotherapy at maximum dose with HbA1c
greater than 8% is considered by the guidelines and a
treatment by oral bitherapy is recommended. But the
appropriate combination of drugs for such bitherapy is
not given by the guidelines. Here, the recommended
action does not fully guide the physician to choose the
appropriate treatment. The rule is therefore incomplete.
Two physicians and a pharmacist familiar with formaliz-
ing guidelines were responsible for the entire process of
identifying and classifying of missing and incomplete
rules.
Generating rules
We implemented the C5.0 decision-tree learning algo-
rithm for the type of treatment, the pharmaco-therapeutic
class, the INN and the dose of prescribed treatments in
463 patient records divided into 16 groups based on their
patient profiles: this process extracted 27 rules (table 2).
The rules generated by the C5.0 algorithm are presented in
the following format:
if antecedent_1 and antecedent_2 ... and antecedent_n
then consequent
where consequent and antecedent_1 through antecedent_n
are all variables. The rule is interpreted as "for records
where antecedent_1 through antecedent_n are all true, con-
sequent  is also likely to be true." Information on the
number of records to which each rule applies – that is, for
which the antecedents are true (Instances) – and the pro-
portion of those records for which the entire rule is true
(Confidence) is given in parenthesis for each rule in Table
2. The proportion of the number of true positive records
to that of true positive and false positive records classified
by the rules (Precision) for each model is also reported in
square brackets. For example, in the last row of Table 2,
for the profile number 16 which comprised 123 cases, the
algorithm found a rule for the type of treatment in 114
records (Instances): it proposed prescribing insulin alone
or with anti-diabetic drugs. The rule was true for all of 114
The decision-tree of the French national guidelines for the management of type 2 diabetes Figure 1
The decision-tree of the French national guidelines for the management of type 2 diabetes. Bubbles represent 
conditions and branches represent actions. Missing or incomplete conditions and actions are shown in bold. OAD: Oral anti-
diabetic drugs; Insulin [+OAD]: insulin alone or with oral anti-diabetic drugs.B
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Table 1: Possible patient conditions and their corresponding actions from the guidelines
Conditions Actions
Profile # Number of 
patients
Acute 
symptoms
HbA1c (%) Ongoing type 
of treatment
BMI* 
(Kg/m2)
Renal 
insufficiency
Elderly Type of 
treatment
Pharmaco-
therapeutic 
class
International non 
proprietary name
Dose
1 2 Yes Any Any Any Any Any Insulin therapy Insulin NM*** NM***
21 6 N o ≤ 6.5 Any Any Any Any The same as 
ongoing 
treatment
The same as 
ongoing 
treatment
The same as ongoing 
treatment
The same as 
ongoing 
treatment
3 7 No Between 6.6 
and 8
Diet and 
Exercise
Any Any Any Evaluate risk-
benefit of 
continuing or 
changing the 
treatment
NM*** NM*** NM***
4 51 No Between 6.6 
and 8
Monotherapy Any Any Any Evaluate risk-
benefit versus 
of continuing 
or changing 
the treatment
NM*** NM*** NM***
5 59 No Between 6.6 
and 8
Bitherapy Any Any Any NM*** NM*** NM*** NM***
6 16 No Between 6.6 
and 8
Tritherapy Any Any Any NM*** NM*** NM*** NM***
7 84 No Between 6.6 
and 8
Insulin 
[+OAD]**
Any Any Any NM*** NM*** NM*** NM***
8 2 No >8 Diet and 
Exercise
Any, other than "BMI ≥ 28 
and no renal insufficiency"
No Monotherapy Any NM*** NM***
9 1 No >8 Diet and 
Exercise
Any, other than "BMI ≥ 28 
and no renal insufficiency"
Yes Monotherapy Any, other than 
long acting 
sulfonylurea
NM*** NM***B
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10 2 No >8 Diet and 
Exercise
≥ 28 No Any Monotherapy Biguanides Metformine NM***
11 24 No >8 Oral 
monotherapy 
not at 
maximum dose
Any Any Any Oral 
monotherapy
The same as 
ongoing 
treatment
NM*** Increase dose 
until reaching 
the maximum 
tolerated
12 1 No >8 Oral 
monotherapy 
at maximum 
dose
Any Any Any Oral bitherapy NM*** NM*** NM***
13 39 No >8 Oral bitherapy 
with any 
combination 
other than 
"Oral bitherapy 
with biguanides 
and 
sulfonylurea at 
maximum 
dose"
Any Any Any Oral bitherapy Biguanides and 
sulfonylurea
NM*** NM***
14 18 No >8 Oral bitherapy 
with biguanides 
and 
sulfonylurea at 
maximum dose
Any Any Any Insulin 
[+OAD]**
Insulin 
[+OAD]**
NM*** NM***
15 18 No >8 Oral tritherapy Any Any Any NM*** NM*** NM*** NM***
16 123 No >8 Insulin 
[+OAD]**
Any Any Any NM*** NM*** NM*** NM***
* BMI: body mass index
** Insulin [+OAD]: insulin alone or with oral anti-diabetic drugs
*** NM: not mentioned in the guidelines
Table 1: Possible patient conditions and their corresponding actions from the guidelines (Continued)BMC Medical Informatics and Decision Making 2009, 9:28 http://www.biomedcentral.com/1472-6947/9/28
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instances, i.e. both conditions and the action were true for
all of these records (Confidence: 1.0). Furthermore, the
proportion of true positive records to the total number of
true positive and false positive records (Precision) was
100% for the model (which means that there were no
false positive records for this model). The algorithm could
not however find any rules for the remaining 9 (= 123-
114) records in this profile.
When the same action was applied to all patients of a sam-
ple without considering any condition, the result was only
a default rule with its precision. A default rule is a rule that
represents a non-conditional action. For example, we
applied the algorithm for learning the pharmaco-thera-
peutic class of drugs in a group of ten patients for whom
the C5.0 model had already proposed tritherapy in a pre-
vious step (see the next-to-last line of Table 2). The fourth
column of Table 2 shows that all of the ten patients were
treated with biguanides, sufonylurea, and alpha glucosi-
dase inhibitors. As there was no other combination of
pharmaco-therapeutic classes to learn, the algorithm can-
not produce a real tree (or it can produce a tree with only
one branch), which we call a default rule.
Rules pertaining to the choice of the type of treatment
We used the C5.0 decision-tree learning algorithm for
every group of patients with profiles for which the type of
treatment was missing, incomplete or imprecise (profile
numbers 3 – 7, and 15 – 16, see Table 1). We considered
the type of treatment as a dependent variable, and all
other relevant variables as independent. The algorithm
extracted 11 rules from physicians' prescriptions for some
of these profiles (Table 2). For example, it revealed that for
patients who were already under tritherapy and had
HbA1c > 8% (profile 15), physicians prescribed insulin
therapy with or without oral anti-diabetic drugs if morn-
ing glycemia was greater than 230 mg/dl; if it was lower,
they continued tritherapy.
Rules pertaining to the choice of the pharmaco-
therapeutic class of drugs
We considered patient profiles for which the type of treat-
ment was known (either through the guidelines or from
the previous step) but the pharmaco-therapeutic class of
medications was missing or incomplete or imprecise (pro-
file numbers 3 – 7, 9, 12, and 14 – 16). We used the C5.0
decision-tree learning algorithm to explore physicians'
choices about the pharmaco-therapeutic classes of drugs
for these cases (Table 2). In creating the model, the phar-
maco-therapeutic class of drugs was considered as a
dependent variable and all other relevant variables
(including the type of treatment) as independent. Thir-
teen rules were extracted concerning pharmaco-therapeu-
tic classes of medications. For example, the algorithm
learnt that for all patients treated with maximum dose
oral monotherapy and having HbA1c > 8% (profile 12),
physicians prescribed a combination of biguanides and
sulfonylurea.
Rules pertaining to the choice of drugs (international non 
proprietary name) and doses
We considered patient profiles for which the type of treat-
ment and the pharmaco-therapeutic classes of drugs were
already known either directly from the guidelines or from
previous steps (profiles numbered 4 – 9). We used C5.0
decision-tree learning algorithm to extract rules related to
drug choice (according to their INNs). In a following step,
we used the C5.0 learning algorithm to extract rules for
the dose of drugs in profiles for which all other elements
of treatment (namely, type, pharmaco-therapeutic class,
and drug INN) were already known (profiles 11 – 16). The
extraction of rules was less successful in these steps
because the conditions and profiles had been already
multiplied in the previous steps (Table 2), and therefore,
most of groups of patients did not contain enough records
to allow the algorithm to calculate rules. However, we
were able to extract one rule for the drug choice (accord-
ing to its INN) and two rules for drug doses (5th and 6th
columns of table 2). For example, for all patients receiving
bitherapy with HbA1c between 6.6 and 8% (profile 5),
and for whom the learning algorithm had proposed
bitherapy with biguanides and sulfonylurea (56 patients
out of 59), the extracted rule suggested to prescribe invar-
iably metformine and glibenclamide. Also, for patients
with HbA1c above 8% (profile 16), receiving insulin
alone or with oral anti-diabetic drugs, the extracted rule
suggested one daily insulin injection if the patient
received also biguanides and sulfonylurea (Incidence:10
patients), but it suggested two daily insulin injections if
the patient received another combination of oral anti-dia-
betic drugs with the insulin (Incidence:104 patients).
Grafting the rules learnt onto the decision-tree of the 
guidelines
We grafted the rules learnt onto the decision-tree of the
guidelines (figure 2) to assess the readability and under-
standability of the new rules. The resulting grafted deci-
sion-tree covers more clinical situations – especially with
regard to tritherapy and insulin therapy – and provides
much more detailed and elaborated recommendations
than the decision-tree of the original guidelines. Note that
the original guidelines had few rules for insulin therapy,
whereas the grafted guidelines are much more explicit in
this regard.
Comparison with the new version of the guideline
We tried to compare the extracted rules with the new rules
in the updated version of the guidelines to identify simi-
larities. However, the new guidelines were fundamentally
different from the original, for example in providing dif-BMC Medical Informatics and Decision Making 2009, 9:28 http://www.biomedcentral.com/1472-6947/9/28
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Table 2: Patient profiles with missing or incomplete rules, and corresponding rules extracted from the database *
Patient subgroups Learnt rules
Profile # Number of patients For type of treatment 
(instances; confidence 
rate) [rule precision]
For pharmaco- 
therapeutic class 
(instances; confidence 
rate) [rule precision]
For INN (instances; 
confidence rate) 
[rule precision]
For Dose (instances; 
confidence rate) [rule 
precision]
3 7 Diet and exercise (7;1) 
[100%]
Not applicable
4 51 Monotherapy (45;1) 
[100%]
sulfonylurea if 
dyslipidemia (7;0.89), else 
alpha glucosidase 
inhibitors if not already 
under biguanides (3;0.8); 
biguanides by default 
(11;0.92) [100%]
5 59 Bitherapy (56;1) [100%] Biguanides and 
sulfonylurea [100%]
Metformine and 
gibenclamide [100%]
6 16 Insulin [+OAD]** if 
cholesterolemia ≤ 400 
mg/dl (2;0.75), Tritherapy 
if not (12;0.93) [100%]
Biguanides, sulfonylurea 
and alpha glucosidase 
inhibitors if tritherapy 
[100%]
7 84 Insulin [+OAD]** (75;1) 
[100%]
Insulin only if already 
under insulin plus 
biguanides (62;0.65); 
Insulin with biguanides if 
postprandial glycemia 
>184 mg/dl and age<52 
yrs (11;0.92); Insulin with 
sulfonylurea and alpha 
glucosidase inhibitors if 
already under 
sulfonylurea (11;0.63) 
[100%]
12 1 Oral bitherapy 
(mentioned in the 
guideline)
Biguanides and 
sulfonylurea [100%]
13 39 Oral bitherapy 
(mentioned in the 
guideline)
Biguanides and 
sulfonylurea if bitherapy 
[100%]
14 18 Insulin [+OAD]** 
(mentioned in the 
guideline)
15 18 Insulin [+OAD]** if 
morning glycemia >230 
mg/dl (8;0.8), tritherapy if 
not (10;0.92) [100%]
Biguanides, sulfonylurea 
and alpha glucosidase 
inhibitors if tritherapy 
[100%]
16 123 Insulin [+OAD]** (114;1) 
[100%]
Insulin only if already 
under insulin plus 
sulfonylurea or insulin 
only (72;0.78); Insulin plus 
biguanides if already 
under insulin plus 
biguanides (24.5;0.83); 
insulin plus biguanides and 
sulfonylurea if not 
(17;0.36) [90.9%]
One injection of Insulin if 
accompanied by 
biguanides or sulfonylurea 
(10;0.83); Two injections 
of insulin [+OAD]** 
(104;0.79) [72.7%]
* Rules are separated according to the typology of treatment: the level of detail increases from left to right. Following each rule, its number of 
instances and confidence rate are presented in parentheses and the rule precision is given in square brackets.
** Insulin [+OAD]: Insulin alone or with oral anti-diabetic drugs.BMC Medical Informatics and Decision Making 2009, 9:28 http://www.biomedcentral.com/1472-6947/9/28
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ferent HbA1c thresholds for each type of treatment. Con-
sequently, it was difficult to make comparisons. In this
work, we expressly did not seek to learn rules to replace
existing evidence-based rules in the original guidelines. As
a result, the grafted decision-tree retained the basic struc-
ture of the original guidelines, which was different from
that of the new version. A one-by-one comparison of our
rules with the newer guideline was therefore not possible.
Nevertheless, we observed some similarities. One major
structural similarity was the recommendation of oral tri-
therapy for patients under bi- or tritherapy. The original
guidelines did not acknowledge the usefulness of oral tri-
therapy in the treatment of type 2 diabetes. We learnt
from the database that tritherapy was prescribed by physi-
cians under some circumstances during 2003 and 2004,
and this in spite of their contemporary guidelines. The
usefulness of tritherapy was confirmed by the new version
of the guidelines in 2006.
A tree entirely based on physicians' decisions
Out of intellectual curiosity, we constructed the decision-
tree corresponding to physicians' decisions, and com-
pared it to the original and the new guidelines. We
applied the C5.0 decision-tree learning algorithm to the
entire database to extract rules that explained physicians'
prescriptions on the basis of patient variables. We filtered
all patient variables except for those used by the guide-
lines to force our algorithm to generate rules which could
be comparable with those of the guidelines (Figure 3).
Physicians -like the new guidelines- used multiple thresh-
olds of HbA1c for each type of treatment (Figure 3), but
their thresholds were generally higher than those used by
the guidelines (8.4%, 9.6% and 10.3% versus 6%, 6.5%
and 8%). Physicians, again like the guidelines, used BMI
for decisions concerning the pharmaco-therapeutic class
and the choice of drugs (INN). The treatment types how-
ever were dependent only on the current types, and physi-
cians did not use other patient conditions when making
these decisions. This learnt algorithm appears to be more
naive than that could be constructed in combination with
the guidelines.
The decision-tree of the original guideline with the learnt rules grafted on it Figure 2
The decision-tree of the original guideline with the learnt rules grafted on it. Bubbles represent conditions and 
branches represent actions. The grafted rules are shown in bold. OAD: Oral anti-diabetic drugs; Insulin [+OAD]: insulin alone 
or with oral anti-diabetic drugs.BMC Medical Informatics and Decision Making 2009, 9:28 http://www.biomedcentral.com/1472-6947/9/28
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Discussion and conclusion
We used an example to demonstrate how to explore the
knowledge gaps in guidelines, and how to use data min-
ing techniques to extract rules from patient records to pro-
vide supplementary information for these knowledge
gaps. The extracted rules permitted us to complete the
decision-tree of the guidelines studied up to the level of
pharmaco-therapeutic class of medications for all patient
profiles, and up to the level of drug choice (according to
the INN) and dose for some profiles. With a database con-
taining more patient records, it would be probably possi-
ble to fill in all gaps of the guidelines up to the level of
dose for all patient profiles.
As we make use of general concepts of the guidelines and
not their disease-specific characteristics, our approach
may be applied with little change to other therapeutic
guidelines at least in the domain of chronic diseases.
We have already proposed a method using a decision-tree
learning algorithm for the evaluation of a guideline-based
decision support system [17]. The current approach we
propose is however different from that of our previous
study, because in this study we aimed at exploring physi-
cians' prescriptions rather than evaluating the results of a
system, and consequently, we applied the decision-tree
learning algorithm to selected groups of patient records
rather than to the whole database.
The use of machine learning techniques for creating
guidelines from data has been suggested previously [9-
11,18-20]. However, we proposed a new our approach,
using the data mining for enriching the guidelines and not
for creating them from scratch.
Although the validity of the rules extracted in our
approach depends on the quality of prescriptions and the
size of the database; the validity of the method itself is not
dependent of these elements.
We showed that some of the decision rules extracted from
physicians' prescriptions were similar to those added to
the new version of the guidelines released three years after
the database was being filled. This suggests that the thera-
peutic reasoning of experienced physicians was in some
ways ahead of their contemporary guidelines, i.e. they
could "anticipate" the guidelines update. This is presuma-
bly because guidelines are based on medical evidence, and
their development is time consuming; consequently, the
results of medical progress appear in guidelines only after
a delay, whereas physicians' practice is generally influ-
enced by the most recently published articles [21].
Although not initially among our objectives, we con-
structed the whole decision-tree corresponding to physi-
cians' decisions by using the algorithm with the entire
database. This revealed that some aspects of physicians'
therapeutic decisions (for example the usefulness of tri-
therapy, or the use of different HbA1c thresholds for dif-
ferent types of treatment) were similar to the newer
version of the guidelines. However, we did not intend to
infer a complete set of guidelines. We do believe that
guidelines must be as evidence-based as possible, and the
evidence must come from scientific studies (clinical trials,
etc). As a result, the approach proposed in this article can
be considered useful when appropriate scientific evidence
does not exist but data corresponding to the opinion of
leading experts – whose practice can be considered as
standard or optimal for the medical issues considered –
are available.
Reconstruction of physicians' decision-tree using the C5.0 learning algorithm with instances and confidence rate for each rule  in parentheses Figure 3
Reconstruction of physicians' decision-tree using the C5.0 learning algorithm with instances and confidence 
rate for each rule in parentheses. Only the rules leading to the choice of the type of treatment are represented. CrCl: cre-
atinine clearance; OAD: oral anti-diabetic drugs.BMC Medical Informatics and Decision Making 2009, 9:28 http://www.biomedcentral.com/1472-6947/9/28
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We used the C5.0 decision-tree learning algorithm. C5.0
models are robust in the presence of problems such as
missing data and large numbers of input fields. They tend
to be easier to understand than some other model types,
because the interpretation of the rules derived from the
model is very straightforward. C5.0 models also allow the
use of a powerful boosting method for increasing the
accuracy of classification.
A common potential limitation of decision-tree learning
algorithms is overfitting [22]. This occurs when the deci-
sion-tree characterizes too much detail, leaving no place
for fitting future cases. The C5.0 decision-tree learning
algorithm is probably less susceptible to this problem
than its predecessor, C4.5, because it generates smaller
decision-trees. The automatic pruning of the Simple Mode
of C5.0 also reduces overfitting [15].
Our method can be used as a simple and quick way to
generate practice-based decision-rules for knowledge gaps
in guidelines. For example, the authors and editors of
guidelines could use our method as a support for discuss-
ing "expert opinion" parts of their guidelines. This is espe-
cially useful as supportive approach to the laborious
process of adopting national or international guidelines
for local use [23]. It can also be used to facilitate the
implementation of guidelines in decision support systems
by providing practice-based rules to complete their logical
structure.
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